Quantitative Concept
Novo Nordisk Faces Setback in IRA Litigation, Vows to Appeal
Novo Nordisk, IRA lawsuit, Medicare price negotiations, legal setback, appeal
Biogen Lifts Outlook as Leqembi Sales Accelerate in Q2
Biogen, Leqembi, Q2 earnings, Alzheimer’s drug, cost cuts, profit outlook
FDA Approves Broader Label for GSK’s Jemperli in First-Line Endometrial Cancer
FDA, GSK, Jemperli, dostarlimab-gxly, endometrial cancer, chemotherapy, carboplatin, paclitaxel, mismatch repair proficient, microsatellite stable, overall survival, progression-free survival
IRA Drug Price Reductions Unlikely to Harm Biotech Innovation, Studies Suggest
Inflation Reduction Act, IRA, drug price negotiations, biotech innovation, Medicare, pharmaceutical industry
Eisai’s Alzheimer’s Drug Leqembi Shows Long-Term Benefits, Despite Study Limitations
Eisai, Leqembi, Alzheimer’s drug, long-term benefits, study limitations, cognitive decline, amyloid plaques, Biogen
Pinetree Therapeutics Secures $17M in Funding to Advance Targeted Protein Degraders
Pinetree Therapeutics, targeted protein degraders, TPD, Series A funding, pharmaceutical development
NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns
NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection
AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform
Fierce Biotech Layoff Tracker 2024: GlycoMimetics Cuts 80% of Company; Anokion Undergoes Cuts
Biotech Layoffs, GlycoMimetics, Anokion, Pharmaceutical Industry, Job Cuts, Cost Reduction
President Biden Highlights Achievements in Lowering Prescription Drug Costs as He Steps Down from Re-election Campaign
President Biden, drug pricing, re-election campaign, Medicare, Inflation Reduction Act, prescription drug costs, health care costs, pharmaceutical industry